VA
MRVI icon

Vident Advisory’s Maravai LifeSciences MRVI Stock Holding History

Vident Advisory’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-110,567
Closed -$244K – 1668
2025
Q1 		$244K Buy
110,567
+82,182
+290% +$325K ﹤0.01% 1350
2024
Q4 		$155K Sell
28,385
-98
-0.3% -$631 ﹤0.01% 1379
2024
Q3 		$237K Sell
28,483
-8,425
-23% -$72.8K 0.01% 1222
2024
Q2 		$264K Buy
36,908
+12,169
+49% +$105K 0.01% 1173
2024
Q1 		$214K Buy
24,739
+9,497
+62% +$64.3K ﹤0.01% 1182
2023
Q4 		$99.8K Sell
15,242
-18,943
-55% -$122K ﹤0.01% 1281
2023
Q3 		$342K Buy
+34,185
New +$375K 0.01% 843

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
MFS
Mirabella Financial Services London, United Kingdom $1.06B AUM 19.83% 1-Year Est. Return
PD
Point72 (DIFC) Dubai, United Arab Emirates $1.53B AUM 15.83% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Vident Advisory's MRVI Position: Q2 2025 in Review

Vident Advisory sold out of Maravai LifeSciences (MRVI) in Q2 2025, closing a stake of 110,567 shares — an estimated $244K sold.

Vident Advisory first reported a position in MRVI in Q3 2023 and held it in 7 quarters. The position peaked at $342K in Q3 2023. 150 funds tracked by Wall St. Rank hold MRVI as of Q2 2025.

  • Vident Advisory reported no remaining Maravai LifeSciences position as of Q2 2025 after selling out during the quarter.
  • Vident Advisory sold 110,567 Maravai LifeSciences shares in Q2 2025, an estimated $244K.
  • Vident Advisory first reported a position in Maravai LifeSciences in Q3 2023 and held it in 7 quarters.
  • Vident Advisory's Maravai LifeSciences position peaked at $342K in Q3 2023.
  • 150 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2025.

Based on Vident Advisory's 13F filing for Q2 2025, filed 14 Aug 2025.